Mesoblast Ltd (MESO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Mesoblast Ltd (MESO) has a cash flow conversion efficiency ratio of -0.027x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-15.56 Million) by net assets ($574.68 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Mesoblast Ltd - Cash Flow Conversion Efficiency Trend (2005–2025)
This chart illustrates how Mesoblast Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Mesoblast Ltd total liabilities for a breakdown of total debt and financial obligations.
Mesoblast Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Mesoblast Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Stoke Therapeutics Inc
NASDAQ:STOK
|
-0.099x |
|
Bellring Brands LLC
NYSE:BRBR
|
0.006x |
|
Silicon2 Co. Ltd.
KQ:257720
|
0.069x |
|
Dongguan Eontec Co Ltd
SHE:300328
|
-0.045x |
|
Sirius Real Estate Ltd
JSE:SRE
|
0.019x |
|
Nantong Jiangshan Agrochemical & Chemicals Co Ltd
SHG:600389
|
0.047x |
|
Mednax Inc
NYSE:MD
|
0.154x |
|
Pharvaris BV
NASDAQ:PHVS
|
-0.098x |
Annual Cash Flow Conversion Efficiency for Mesoblast Ltd (2005–2025)
The table below shows the annual cash flow conversion efficiency of Mesoblast Ltd from 2005 to 2025. For the full company profile with market capitalisation and key ratios, see MESO company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | $597.44 Million | $-49.95 Million | -0.084x | +17.12% |
| 2024-06-30 | $480.36 Million | $-48.46 Million | -0.101x | +19.98% |
| 2023-06-30 | $501.84 Million | $-63.27 Million | -0.126x | +4.74% |
| 2022-06-30 | $497.04 Million | $-65.78 Million | -0.132x | +27.87% |
| 2021-06-30 | $581.40 Million | $-106.68 Million | -0.183x | -78.83% |
| 2020-06-30 | $549.33 Million | $-56.37 Million | -0.103x | +14.59% |
| 2019-06-30 | $481.05 Million | $-57.79 Million | -0.120x | +12.56% |
| 2018-06-30 | $546.01 Million | $-75.01 Million | -0.137x | +25.64% |
| 2017-06-30 | $516.77 Million | $-95.47 Million | -0.185x | -10.89% |
| 2016-06-30 | $528.16 Million | $-88.00 Million | -0.167x | +16.58% |
| 2015-06-30 | $609.36 Million | $-121.71 Million | -0.200x | -39.49% |
| 2014-06-30 | $571.72 Million | $-81.86 Million | -0.143x | -66.87% |
| 2013-06-30 | $630.27 Million | $-54.08 Million | -0.086x | +43.03% |
| 2012-06-30 | $478.85 Million | $-72.12 Million | -0.151x | -171.78% |
| 2011-06-30 | $515.84 Million | $108.23 Million | 0.210x | +182.38% |
| 2010-06-30 | $37.92 Million | $-9.66 Million | -0.255x | +28.89% |
| 2009-06-30 | $25.79 Million | $-9.24 Million | -0.358x | -51.39% |
| 2008-06-30 | $26.22 Million | $-6.20 Million | -0.237x | +46.61% |
| 2007-06-30 | $20.54 Million | $-9.10 Million | -0.443x | -66.55% |
| 2006-06-30 | $11.97 Million | $-3.18 Million | -0.266x | -747.50% |
| 2005-06-30 | $19.26 Million | $-604.81K | -0.031x | -- |
About Mesoblast Ltd
Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company's proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. It offers Remestemcel-L, which is in Phase III clinical trials for the treatment of systemic… Read more